Provention Bio's diabetes drug gains PRIME status; Avrobio earns orphan status
→ Two days after its J&J licensed Chron’s disease drug flunked a Phase IIa study, Provention Bio announced its lead drug, PRV-031 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
